Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Oncology·MeSH: Recurrence
Prevalence
30.0 / 100K
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| tak-007 | TAKEDA PHARMACEUTICAL CO LTD (TKPHF) |
Phase 1/Phase 2(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)?
BioSniper tracks 2 drugs in development for Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) across 1 company.
How many clinical trials target Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)?
There are 1 clinical trial targeting Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) tracked by BioSniper.
What is the prevalence of Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)?
The estimated prevalence of Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) is approximately 30.0 per 100,000 population.
Deep-dive into Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis